© 2010 Genitourinary Publishing, Inc.
Volume 3, Number 4 Autumn 2005
Guest Editorial
Divided We Fall: How Competition Can Compromise the Cause
Janice P. Dutcher, MD and William P. Bro
Novel Molecular Chaperone, B7-H1, Promising Downstream Target to Improve Kidney Cancer Immunotherapy
R. Houston Thompson, MD and Eugene D. Kwon, MD
Surgical Strategies to Optimize Outcomes in Isolated
Renal Fossa Recurrence Following Nephrectomy
Peter R. Carroll, MD
Report Card on Adjuvant Therapy: Trials Build Enrollment, Enhancing Prospects for New Treatment Options
Tim Eisen, PhD, FRCP
To view this issue, click here.
Volume 3, Number 3 Autumn 2005
Chemotherapy for Rapidly Progressing Renal Cell Carcinoma: To What Extent Do Combinations of Agents Show Potential Activity?
Vladimir Hugec, MD and Janice Dutcher, MD
Allogeneic Hematopoietic Stem-Cell Transplantation for
Metastatic Renal Cell Carcinoma
Yee Chung Cheng, MD, Nizar Tannir, MD, Richard E. Champlin, MD, and Naoto T. Ueno, MD, PhD
Challenges in Kidney Cancer
Fourth International Kidney Cancer Symposium
Highlights, Fourth International Kidney Cancer Symposium, October 2005
To view this issue, click here.
Below are past issues of Kidney Cancer Journal. To view each issue, click on the link below the front cover. To see issues from previous years, click on the dates at the bottom of the page.
Each issue will be presented in a page-turning format, and by reading the directions to the left of the cover page, you will be able to go forward and backwards within the issue, enlarge and reduce pages, view the table of contents in the upper left, conduct a search of the entire issue
Volume 3, Number 2 Summer 2005
ASCO 2005 Highlights: Novel Targeted Therapies Move
Closer to Clinical Applications
Improving Prognostication in Renal Cell Carcinoma: Novel
Molecular Biomarkers as Predictors of Outcome and Survival
Tarek Mekhail, MD, MSc, FRCSI, FRCSEd
Close-up on New ECOG Trial: How It Could Define
Paradigm for Combination Targeted Therapy
Keith Flaherty, MD
Challenging Cases in Kidney Cancer
Deconstructing the Gold Standard by Recognizing the Pitfalls of Placebo-Controlled Trials in Renal Cell Carcinoma
Martin Gore, PhD, FRCP
To view this issue, click here.
Volume 3, Number 1 Spring 2005
Cytokine Working Group: New Paradigm in IL-2 Therapy
Based on Improved Patient Selection
David McDermott, MD
Meeting Highlights: Miami, February 2005
Adjuvant Therapy: New Agents May Finally Provide the Long-Awaited Option
Robert Dreicer, MD
Long-Term Survival with Chimeric Monoclonal Antibody
WX-G250 in Stage IV Metastatic Renal Cell Carcinoma
Carola Mala, P Kloepfer, Ivar Bleumer, Peter Mulders, Egbert Oosterwijk, Alexander Knuth, MD, Elke Jaeger, MD, Salah-Eddin Al-Batran,J Beck, Rainer Hofmann, MD, Zoltan Varga, MD, Wim HJ Kruit, and Paul Bevan, PhD
Challenging Cases in Kidney Cancer
Inhibiting the VEGF Signaling Pathway: New Trials Focus on Combination Therapy with Antiangiogenic Agents
Brian I. Rini, MD
Interview with Andrew C. Novick, MD
Evolution in Surgery for RCC: Emerging Concepts in Minimally Invasive Techniques to Preserve Renal Function
To view this issue, click here.
2005
by entering a key word in the upper right field, and print individual pages. Please note that slower internet connections will cause the pages to open, turn, and enlarge more slowly.
When you see an active hyperlink within the general text, an article (not the references) or in an ad unit, you can click that link to send an e-mail or be taken to that web page.
To view past issues from other years, click on one of the years below.
